A personal history of the CAMPATH-1H antibody.
The recent licensing of CAMPATH-1H (alemtuzumab) for the treatment of patients with refractory chronic lymphocytic leukemia has been the culmination of a long journey. This success is in large part due to the persistence, dedication, and commitment of a large number of academic collaborators. The fi...
| Autor principal: | |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
2002
|